Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

Atrasentan, an endothelin receptor antagonist, showed clinically significant albuminuria reduction with minimal signs of fluid retention in phase II trials. We evaluated whether plasma exposure was associated with long‐term outcomes for kidney protection and heart failure in the phase III SONAR tria...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Pharmacol Ther
Prif Awduron: Koomen, Jeroen V., Stevens, Jasper, Bakris, George, Correa‐Rotter, Ricardo, Hou, Fan Fan, Kitzman, Dalane W., Kohan, Donald E., Makino, Hirofumi, McMurray, John J. V., Parving, Hans‐Henrik, Perkovic, Vlado, Tobe, Sheldon W., de Zeeuw, Dick, Heerspink, Hiddo J. L.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2021
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8246733/
https://ncbi.nlm.nih.gov/pubmed/33338269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.2143
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg